Spiro Medical raises $67M Series A for pulmonary neuromodulation in asthma
Summary
Spiro Medical raised $67 million in Series A financing co-led by Andera Partners, Omega Funds, and Sherpa Healthcare Partners, with participation from HSG, Supernova Invest, Northern Light Venture Capital, and Hero Inc. The Irvine, California-based company is developing a first-of-its-kind Pulmonary Neuromodulation System to treat asthma by delivering electrical signals to nerves that regulate the airways. Proceeds will fund product development and clinical trials for FDA approval.
Why it matters
Spiro Medical is pioneering the first device-based therapy for asthma, a condition affecting over 28 million Americans and 300 million people worldwide. By applying neuromodulation principles to respiratory disease, the company could open an entirely new clinical indication for bioelectronic medicine, offering an alternative to drugs and biologics that have limited remission rates.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial